BMJ Open

Page 26 of 30

PRISMA-P 2015 Checklist

This checklist has been adapted for use with protocol submissions to *Systematic Reviews* from Table 3 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews* 2015 **4**:1

Section/topic	"	Checklist item	Information reported Line		
	#		Yes	No	number(s)
ADMINISTRATIVE IN	IFORMAT	TION			
Title					
Identification	1a	Identify the report as a protocol of a systematic review			1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such			Not applicable
Registration	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number in the Abstract			48
Authors					
Contact	За	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author			3,6
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review			370-374
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments			Not applicable
Support					
Sources	5a	Indicate sources of financial or other support for the review			377-378
Sponsor	5b	Provide name for the review funder and/or sponsor			377
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol			378-379
INTRODUCTION					
Rationale	6	Describe the rationale for the review in the context of what is already known			91-107
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)			135-141,
					176-186



For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2

Page 27 of 30 BMJ Open

40

41

42

43

49

Information reported Line Section/topic Checklist item number(s) Yes No **METHODS** Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report \boxtimes 163-165,173-Eligibility criteria characteristics (e.g., years considered, language, publication status) to be used as criteria for 186,189-197 eligibility for the review \boxtimes Describe all intended information sources (e.g., electronic databases, contact with study authors, 161-170, 191-Information sources trial registers, or other grey literature sources) with planned dates of coverage 193 \boxtimes Present draft of search strategy to be used for at least one electronic database, including planned 159 Search strategy limits, such that it could be repeated STUDY RECORDS \boxtimes Describe the mechanism(s) that will be used to manage records and data throughout the review 204-207 Data management State the process that will be used for selecting studies (e.g., two independent reviewers) through \boxtimes 207-215 11b Selection process each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis) Describe planned method of extracting data from reports (e.g., piloting forms, done independently, \boxtimes Data collection 220-236 in duplicate), any processes for obtaining and confirming data from investigators process List and define all variables for which data will be sought (e.g., PICO items, funding sources), any \boxtimes 176-186, 377 12 Data items pre-planned data assumptions and simplifications Outcomes and List and define all outcomes for which data will be sought, including prioritization of main and \boxtimes 240-249 13 prioritization additional outcomes, with rationale Describe anticipated methods for assessing risk of bias of individual studies, including whether this Not applicable Risk of bias in will be done at the outcome or study level, or both; state how this information will be used in data individual studies synthesis DATA Not applicable Describe criteria under which study data will be quantitatively synthesized If data are appropriate for quantitative synthesis, describe planned summary measures, methods of Not applicable handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I², Kendall's tau) Synthesis Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-Not applicable 15c regression) \boxtimes 250 If quantitative synthesis is not appropriate, describe the type of summary planned 15d Not applicable Meta-bias(es) Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective **BioMed** Central

The Open Access Publisher

BMJ Open

Page 28 of 30

Section/topic	#	Checklist item	Information reported		_
			Yes	No	number(s)
		reporting within studies)			
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)			Not applicable





For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml